Trial Profile

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NEO-2734 (Primary)
Indications Carcinoma; Chronic lymphocytic leukaemia; Myelofibrosis; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Epigenetix

Most Recent Events

19 Sep 2024 Protocol amended to include patients with chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and other targeted hematological malignancies.
19 Sep 2024 Planned number of patients changed from 50 to 75.
19 Sep 2024 Planned End Date changed from 1 Sep 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com